Skip to main content

Table 3 Mean rifampin plasma concentrations (μg/ml) in human immunodeficiency virus (HIV)-infected and HIV-uninfected children being treated for tuberculosis on enrolment after 1-month and 4-months of treatment.

From: Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

Time after dosing (hours) Enrolment (SD) 4 months (SD)
  N Human immunodeficiency virus-infected N Human immunodeficiency virus-uninfected P
value
N Human immunodeficiency virus-infected N HIV-uninfected P value
0.75 21 2.35(2.54) 32 4.02(5.10) 0.12 20 3.11(3.45) 33 3.84(3.72) 0.47
1.5 21 4.26(1.96) 33 5.63(4.07) 0.10 21 4.28(2.66) 33 5.31(3.01) 0.19
2.01 21 3.90(1.67) 33 5.07(3.59) 0.11 21 4.00(2.04) 32 4.61(2.43) 0.33
3.0 20 3.01(1.96) 33 3.93(3.50) 0.22 21 3.43(2.83) 32 3.58(2.42) 0.84
4.0 21 2.22(1.67) 32 3.17(4.54) 0.29 20 2.60(1.74) 32 2.41(1.94) 0.72
6.0 16 1.12(1.41) 28 1.95(4.45) 0.37 17 1.09(0.88) 30 0.88(0.96) 0.47
C max (μg/ml) 21 4.91(2.03) 33 6.92(5.88) 0.08 21 5.67(3.30) 33 6.26(3.41) 0.53
T max (hour) 21 1.80(0.87) 33 1.67(0.93) 0.62 21 2.17(1.30) 33 1.71(0.88) 0.17
AUC0–6 (μg/hour/ml) 21 14.88(7.43) 32 18.07(12.52) 0.25 21 16.52(8.84) 33 17.94(10.36) 0.59
  1. 1The 2-hour plasma concentrations are calculated as [(2/3)(1.5 hour value+(1/3)(3.0 hour value)].
  2. C max = observed maximum value for each individual; T max = the time at which C max was recorded.
  3. AUC, area under the curve.